vs
Beneficient（BENF）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Beneficient的1.9倍（$35.5M vs $18.7M），Beneficient净利率更高（106.7% vs -304.2%，领先410.9%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 322.5%）
Beneficient是一家专注于另类资产流动性解决方案的金融服务企业，为私募股权、对冲基金份额、实物资产等非流动资产持有者提供定制化服务，客户主要涵盖北美地区的机构投资者、高净值人士及家族办公室。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
BENF vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.9倍
$18.7M
营收增速更快
RXRX
高出359.2%
322.5%
净利率更高
BENF
高出410.9%
-304.2%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $35.5M |
| 净利润 | $19.9M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 21.1% | -304.8% |
| 净利率 | 106.7% | -304.2% |
| 营收同比 | 322.5% | 681.7% |
| 净利润同比 | 330.5% | 39.6% |
| 每股收益（稀释后） | — | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BENFRXRX
| Q4 25 | $18.7M | $35.5M | ||
| Q3 25 | $-2.8M | $5.2M | ||
| Q2 25 | $-12.6M | $19.2M | ||
| Q1 25 | $-31.0M | $14.7M | ||
| Q4 24 | $4.4M | $4.5M | ||
| Q3 24 | $8.6M | $26.1M | ||
| Q2 24 | $10.0M | $14.4M | ||
| Q1 24 | — | $13.8M |
净利润BENFRXRX
| Q4 25 | $19.9M | $-108.1M | ||
| Q3 25 | $-17.9M | $-162.3M | ||
| Q2 25 | $-92.6M | $-171.9M | ||
| Q1 25 | $-44.6M | $-202.5M | ||
| Q4 24 | $-8.6M | $-178.9M | ||
| Q3 24 | $9.7M | $-95.8M | ||
| Q2 24 | $44.3M | $-97.5M | ||
| Q1 24 | — | $-91.4M |
毛利率BENFRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率BENFRXRX
| Q4 25 | 21.1% | -304.8% | ||
| Q3 25 | 646.5% | -3327.6% | ||
| Q2 25 | 734.0% | -916.8% | ||
| Q1 25 | 146.3% | -1297.9% | ||
| Q4 24 | -215.3% | -4042.4% | ||
| Q3 24 | -160.2% | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率BENFRXRX
| Q4 25 | 106.7% | -304.2% | ||
| Q3 25 | 648.1% | -3135.3% | ||
| Q2 25 | 734.0% | -894.2% | ||
| Q1 25 | 144.1% | -1373.3% | ||
| Q4 24 | -195.5% | -3935.5% | ||
| Q3 24 | 113.9% | -367.5% | ||
| Q2 24 | 441.1% | -676.6% | ||
| Q1 24 | — | -662.4% |
每股收益（稀释后）BENFRXRX
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.40 | ||
| Q1 24 | — | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.9M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $-128.6M | $1.1B |
| 总资产 | $337.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资BENFRXRX
| Q4 25 | $7.9M | $743.3M | ||
| Q3 25 | $4.9M | $659.8M | ||
| Q2 25 | $7.6M | $525.1M | ||
| Q1 25 | $1.3M | $500.5M | ||
| Q4 24 | $4.1M | $594.4M | ||
| Q3 24 | $4.5M | $427.6M | ||
| Q2 24 | $4.4M | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务BENFRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益BENFRXRX
| Q4 25 | $-128.6M | $1.1B | ||
| Q3 25 | $-142.8M | $1.0B | ||
| Q2 25 | $-120.4M | $919.1M | ||
| Q1 25 | $-34.9M | $933.9M | ||
| Q4 24 | $14.3M | $1.0B | ||
| Q3 24 | $-13.2M | $524.6M | ||
| Q2 24 | $-148.3M | $584.4M | ||
| Q1 24 | — | $401.2M |
总资产BENFRXRX
| Q4 25 | $337.9M | $1.5B | ||
| Q3 25 | $316.2M | $1.4B | ||
| Q2 25 | $334.5M | $1.3B | ||
| Q1 25 | $354.9M | $1.3B | ||
| Q4 24 | $400.0M | $1.4B | ||
| Q3 24 | $368.8M | $726.5M | ||
| Q2 24 | $361.3M | $775.9M | ||
| Q1 24 | — | $557.8M |
负债/权益比BENFRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | 0.0% | 3.5% |
| 现金转化率经营现金流/净利润 | -0.47× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流BENFRXRX
| Q4 25 | $-9.4M | $-46.1M | ||
| Q3 25 | $-14.5M | $-117.4M | ||
| Q2 25 | $-10.8M | $-76.4M | ||
| Q1 25 | $-37.7M | $-132.0M | ||
| Q4 24 | $-10.0M | $-115.4M | ||
| Q3 24 | $-8.6M | $-59.2M | ||
| Q2 24 | $-10.6M | $-82.2M | ||
| Q1 24 | — | $-102.3M |
自由现金流BENFRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | $-10.9M | $-79.6M | ||
| Q1 25 | $-38.8M | $-133.8M | ||
| Q4 24 | $-10.0M | $-116.7M | ||
| Q3 24 | $-8.9M | $-63.8M | ||
| Q2 24 | $-11.3M | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率BENFRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | 86.6% | -413.9% | ||
| Q1 25 | 125.3% | -907.4% | ||
| Q4 24 | -227.2% | -2567.7% | ||
| Q3 24 | -103.7% | -244.6% | ||
| Q2 24 | -112.6% | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度BENFRXRX
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 0.0% | 4.7% | ||
| Q2 25 | -0.8% | 16.4% | ||
| Q1 25 | -3.5% | 12.4% | ||
| Q4 24 | 1.0% | 28.6% | ||
| Q3 24 | 3.1% | 17.5% | ||
| Q2 24 | 6.6% | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率BENFRXRX
| Q4 25 | -0.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.88× | — | ||
| Q2 24 | -0.24× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BENF
| Ben Liquidity | $8.2M | 44% |
| Other | $7.6M | 41% |
| Ben Custody | $2.9M | 16% |
RXRX
暂无分部数据
